NDAINJECTIONINJECTABLEPriority Review
Approved
Apr 1968
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
DESFERAL (deferoxamine mesylate) by Gland Pharma is reactions. Approved for intracerebral hemorrhage. First approved in 1968.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Deferoxamine mesylate is a chelating agent approved since 1968 for iron overload conditions, including intracerebral hemorrhage. It works by binding ferric iron from ferritin and hemosiderin, rendering it available for excretion. The drug is administered via injection and does not affect iron in hemoglobin, cytochromes, or transferrin-bound sources.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), brand teams will shift focus from growth to lifecycle management and cost optimization strategies.
Mechanism of Action
reactions. It readily chelates iron from ferritin and hemosiderin but not readily from transferrin; it does not combine with the iron from cytochromes and hemoglobin. Deferoxamine mesylate does not cause any demonstrable increase in the excretion of electrolytes or trace metals. Theoretically, 100…
Worked on DESFERAL at Gland Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.